Biography

Dr Eyad Elkord has currently a Professor of Immunology position with the Natural & Medical Sciences Research Centre, University of Nizwa, Oman; and an Honorary Professor position with University of Salford, UK. He received his BSc in 1995 from Al-Quds University (Jerusalem), an MPhil in 2001 from Bergen University (Norway) and a PhD in Tumour Immunology in 2005 from University of Wales College of Medicine, Cardiff University (UK). He was a Postdoctoral Scientist (Jan 2005-Dec 2007) at the Paterson Institute for Cancer Research, University of Manchester (UK), and was promoted to a Research Fellow/Group Leader of the Clinical Immunotherapy Laboratory at the University of Manchester (Jan 2008-Nov 2010). He then undertook a Lecturer position with University of Salford (Dec 2010-July 2012) and was promoted in August 2012 to a Senior Lecturer position. He moved to the College of Medicine & Health Science, United Arab Emirates University in 2012 and was an Associate Professor of Immunology until September 2016. He then worked as a Principal Investigator at Qatar Biomedical Research Institute, and a Professor at Hamad Bin Khalifa University, Qatar (July 2016-Nov 2020); and he also had an Honorary Professor position at the Institute of Cancer Sciences-University of Manchester, UK. Dr Elkord is a member of scientific societies including British Society for Immunology, European Academy of Allergology and Clinical Immunology, Immunology Interest Group (National Institutes of Health) and European Macrophage and Dendritic Cell Society. He is the recipient of UAE University Award for Excellence in Scholarship in 2016, and the Dean's annual research prize, College of Science & Technology, University of Salford, UK in 2012. He is an awardee of certificates of achievement for publishing in top journals and bringing recognition to UAE University in 2013, 2014 and 2015. Dr Elkord is an editorial board member for peer-reviewed international journals such as Frontiers in Immunology & Oncology (specialty Cancer Immunity & Immunotherapy), BMC Cancer, Vaccines and Journal of Immunology Research. He is a reviewer to many international journals and well-known funding agents including UK Medical Research Council, Wellcome Trust, European Research Council, Dutch Research Council, Yorkshire Cancer Research, Belgian Foundation against Cancer, Leukemia Lymphoma Research and Breast Cancer Now. He has presented his work at different national and international meetings and conferences. Dr Elkord’s research in the area of immune regulation is well recognized, and he has edited three books for Frontiers in Immunology in 2013, Journal of Immunology Research in 2018 and Seminars in Cancer Biology in 2020. Dr Elkord has 120 publications in peer reviewed high-impact international journals with more than 9000 citations and an h-index of 43 and M-index of 2.7. In recognition of his research influence, Dr Elkord has been named in Stanford University’s global list of top 2% Scientists for three consecutive years (2019-2021), achieving the position in top 0.26% in Immunology subfield.

Area of Interest:

Biomedical Sciences

100%

Cell Culture

62%

Cancer Immunology

90%

Immunohistochemistry

75%

Western Blot

55%

Research Publications in Numbers

Books
6

Chapters
0

Articles
125

Abstracts
36

Selected Publications

Alsalman, A., M.A. Al-Mterin, K. Murshed, F. Alloush, S.T. Al-Shouli, S.M. Toor and E. Elkord, 2022. Circulating and tumor-infiltrating immune checkpoint-expressing CD8+ Treg/T cell subsets and their associations with disease-free survival in colorectal cancer patients. Cancers, Vol. 14. 10.3390/cancers14133194.
CrossRef | Direct Link |
Alsalman, A., M.A. Al-Mterin, A. Abu-Dayeh, F. Alloush, K. Murshed and E. Elkord, 2022. Associations of complete blood count parameters with disease-free survival in right- and left-sided colorectal cancer patients. J. Pers. Med., Vol. 12. 10.3390/jpm12050816.
CrossRef | Direct Link |
Alsalman, A., M.A. Al-Mterin and E. Elkord, 2022. Role of T regulatory cells and myeloid-derived suppressor cells in COVID-19. J. Immunol. Res., Vol. 2022. 10.1155/2022/5545319.
CrossRef | Direct Link |
Alahdal, M. and E. Elkord, 2022. Promising use of immune cell-derived exosomes in the treatment of SARS-CoV-2 infections. Clin. Transl. Med., Vol. 12. 10.1002/ctm2.1026.
CrossRef | Direct Link |
Al-Mterin, M.A., K. Murshed and E. Elkord, 2022. Correlations between circulating and tumor-infiltrating CD4+ treg subsets with immune checkpoints in colorectal cancer patients with early and advanced stages. Vaccines, Vol. 10. 10.3390/vaccines10091471.
CrossRef | Direct Link |
Al-Mterin, M.A., K. Murshed and E. Elkord, 2022. Correlations between circulating and tumor-infiltrating CD4+ T cell subsets with immune checkpoints in colorectal cancer. Vaccines, Vol. 10. 10.3390/vaccines10040538.
CrossRef | Direct Link |
Al-Mterin, M.A. and E. Elkord, 2022. Myeloid-derived suppressor cells in colorectal cancer: Prognostic biomarkers and therapeutic targets. Explor. Targeted Anti-tumor Ther., 3: 497-510.
CrossRef | Direct Link |
Toor, S.M., V.S. Nair, R. Saleh, R.Z. Taha and K. Murshed et al., 2021. Transcriptome of tumor-infiltrating T cells in colorectal cancer patients uncovered a unique gene signature in CD4+ T cells associated with poor disease-specific survival. Vaccines, Vol. 9. 10.3390/vaccines9040334.
CrossRef | Direct Link |
Toor, S.M., V.S. Nair, K. Murshed, M.A. Nada and E. Elkord, 2021. Tumor-infiltrating lymphoid cells in colorectal cancer patients with varying disease stages and microsatellite instability-high/Stable tumors. Vaccines, Vol. 9. 10.3390/vaccines9010064.
CrossRef | Direct Link |
Toor, S.M., R. Saleh, V.S. Nair, R.Z. Taha and E. Elkord, 2021. T-cell responses and therapies against SARS‐CoV‐2 infection. Immunology, 162: 30-43.
CrossRef | Direct Link |
Saleh, R., V.S. Nair, K. Murshed, M.A. Nada, E. Elkord and R. Shaheen, 2021. Transcriptome of CD8⁺ tumor-infiltrating T cells: a link between diabetes and colorectal cancer. Cancer Immunol. Immunother., 70: 2625-2638.
CrossRef | Direct Link |
Saleh, R., V.S. Nair, K. Murshed, M.A. Nada, E. Elkord and R. Shaheen, 2021. Correction to: Transcriptome of CD8+ tumor-infiltrating T cells: A link between diabetes and colorectal cancer. Cancer Immunol. Immunother., 70: 2639-2640.
CrossRef | Direct Link |
Parray, A., F.A. Mir, A. Doudin, A. Iskandarani and I.M.M. Danjuma et al., 2021. SnoRNAs and miRNAs networks underlying COVID-19 disease severity. Vaccines, Vol. 9. 10.3390/vaccines9101056.
CrossRef | Direct Link |
Nair, V.S., R. Saleh, S.M. Toor, F.S. Cyprian and E. Elkord, 2021. Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment. Cancer Immunol. Immunother., 70: 2103-2121.
CrossRef | Direct Link |
Nair, V.S., R. Saleh, S.M. Toor, F.S. Cyprian and E. Elkord, 2021. Correction to: Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment. Cancer Immunol. Immunother., 70: 2123-2123.
CrossRef | Direct Link |
Toor, S.M., R.Z. Taha, V.S. Nair, R. Saleh, K. Murshed, M.A. Nada and E. Elkord, 2020. Differential gene expression of tumor-infiltrating CD₃₃⁺ myeloid cells in advanced- versus early-stage colorectal cancer. Cancer Immunol. Immunother., 70: 803-815.
CrossRef | Direct Link |
Saleh, R., S.M. Toor, R.Z. Taha, D. Al-Ali, V.S. Nair and E. Elkord, 2020. DNA methylation in the promoters of PD-L1, MMP9, ARG1, galectin-9, TIM-3, VISTA and TGF-β genes in HLA-DR^– myeloid cells, compared with HLA-DR⁺ antigen-presenting cells. Epigenetics, 15: 1275-1288.
CrossRef | Direct Link |
Saleh, R., S.M. Toor and E. Elkord, 2020. Targeting TIM-3 in solid tumors: Innovations in the preclinical and translational realm and therapeutic potential. Expert Opin. Ther. Targets, 24: 1251-1262.
CrossRef | Direct Link |
Saleh, R., R.Z. Taha, V.S. Nair, S.M. Toor, N.M. Alajez and E. Elkord, 2020. Transcriptomic profiling of circulating HLA-DR^– myeloid cells, compared with HLA-DR⁺ myeloid antigen-presenting cells. Immunol. Invest., 50: 952-963.
CrossRef | Direct Link |
Nair, V.S., R. Saleh, S.M. Toor, R.Z. Taha and A.A. Ahmed et al., 2020. Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer. Clin. Epigenet., Vol. 12. 10.1186/s13148-020-0808-9.
CrossRef | Direct Link |